 |
 |
...I have not seen any information on the web about GPI-1046. Has any body outHi,
there kept on track of the clinical trials?...
The following are my e-mail messages or parts thereof, from last fall/winter regarding Guilford's compound GPI 1046, developed at John's Hopkins and Guilford, and then licensed to Amgen, who named it NIL-A, AMGEN of Thousand Oaks, CA. It is in Phase I trials in Europe.
Go to: http://www.amgen.com/product/Pipeline.html to keep up-to-date, but they are keeping their cards fairly close to the chest right now, and it will be years before it comes to market, if it makes it past all the trials.
Make no mistake, I'm very excited about it and other therapies under development, and would be willing to be part of the Phase II-IV trials, if it continues to show promise and safety--but, reality is reality. Still, I believe that something much better than drug therapy is in our sites.
Keep the faith,
Charlotte
-------------------
"Hi,
It's not called GPI 1046 at Amgen: 1046 is still being used at
John
Hopkins and Guilford as a research tool and not as a commercial
product: The compound, neuroimmunophilin compound, was licensed
to
Amgen ...
http://www.amgen.com/product/Pipeline.html
Neuroimmunophilins Phase 1 [ top ]
Guilford Pharmaceuticals and Amgen have
initiated the first clinical testing of a class of
compounds known as neuroimmunophilins. The
neuroimmunophilin compounds are being
developed to promote nerve regeneration and
repair neurodegenerative disorders. In
preclinical studies, including models of
Parkinson's disease, neuroimmunophilins
demonstrated potential to promote nerve
regeneration and repair. In 1997, Amgen
licensed from Guilford worldwide rights for the
neuroimmunophilins, a novel class of small
molecule neurotrophic agents that may represent
a new approach in the treatment of
neurodegenerative disorders.
Me,"
--
Charlotte A. Mancuso
***************************************************
For advocacy, medical, and other PD-related material, go to:
http://www.onelist.com/subscribe/CurePD-NorCal
------------------------------------------------
BALTIMORE (Dow Jones)--Guilford Pharmaceuticals Inc. (GLFD) received
a
$5
million milestone payment from Amgen Inc. (AMGN) for clinical
developments in
the companies' neuroimmunophilin collaboration.
In a press release Thursday, Guilford said it earned the payment when
Amgen
filed an Investigational New Drug application in the U.S. for the
ligands, which
have demonstrated, in animal testing, the ability to promote re-growth
and
repair of damaged nerves.
The companies seek to develop neuroimmunophilin ligands for Parkinson's
disease,
Alzheimer's disease, stroke, peripheral neuropathies, traumatic brain
injuries,
traumatic spinal cord injuries, multiple sclerosis, ophthalmic
applications, and
two additional undisclosed nonneurological indications.
Under their agreement, Guilford is receiving $13.5 million in research
funding
over three years, will receive royalties on any future product sales
and
is
eligible to receive up to $392 million in development milestones.
Amgen is responsible for conducting all clinical development,
manufacturing and
marketing.
-Michael Squires; Dow Jones Newswires; 201-938-5400
1999 Dow Jones & Company, Inc. All Rights Reserved.
Dennis Nestler wrote:
What a fine Saturday night this is, I got the whole place to myself. I'm--
trying to file all the e-mail I've kept over the past couple of years. I ran
across a post from William Levinson dated 7-16-97 in which he asked if there
was any information on the clinical trials of GPI-1046.Bill also gave the List two sites to read which are......
http://www.parkinson org/texthtms/tcure.htm
http://www.mhsource.com/edu/psytimes/p970401a.htmlI have not seen any information on the web about GPI-1046. Has any body out
there kept on track of the clinical trials?Now all I have to file away is 299 e-mails.
Dennis
58/52